395 related articles for article (PubMed ID: 38111571)
1. Heterogeneity of tertiary lymphoid structures in cancer.
You X; Koop K; Weigert A
Front Immunol; 2023; 14():1286850. PubMed ID: 38111571
[TBL] [Abstract][Full Text] [Related]
2. Harnessing the power of oncolytic virotherapy and tertiary lymphoid structures to amplify antitumor immune responses in cancer patients.
Houel A; Foloppe J; Dieu-Nosjean MC
Semin Immunol; 2023 Sep; 69():101796. PubMed ID: 37356421
[TBL] [Abstract][Full Text] [Related]
3. Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies.
N J; J T; Sl N; Gt B
Oncoimmunology; 2021 Mar; 10(1):1900508. PubMed ID: 33854820
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation.
Domblides C; Rochefort J; Riffard C; Panouillot M; Lescaille G; Teillaud JL; Mateo V; Dieu-Nosjean MC
Front Immunol; 2021; 12():698604. PubMed ID: 34276690
[TBL] [Abstract][Full Text] [Related]
5. Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.
Liu X; Tsang JYS; Hlaing T; Hu J; Ni YB; Chan SK; Cheung SY; Tse GM
Oncologist; 2017 Nov; 22(11):1316-1324. PubMed ID: 28701569
[TBL] [Abstract][Full Text] [Related]
6. Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope.
Jia W; Zhang T; Yao Q; Li J; Nie Y; Lei X; Mao Z; Wang Y; Shi W; Song W
Front Immunol; 2022; 13():870458. PubMed ID: 35844587
[TBL] [Abstract][Full Text] [Related]
7. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment
Xu W; Lu J; Liu WR; Anwaier A; Wu Y; Tian X; Su JQ; Qu YY; Yang J; Zhang H; Ye D
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040418
[TBL] [Abstract][Full Text] [Related]
9. Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application.
Zhang Y; Xu M; Ren Y; Ba Y; Liu S; Zuo A; Xu H; Weng S; Han X; Liu Z
Mol Cancer; 2024 Apr; 23(1):75. PubMed ID: 38582847
[TBL] [Abstract][Full Text] [Related]
10. Of mice and lymphoid aggregates: modeling tertiary lymphoid structures in cancer.
Vaccaro A; van de Walle T; Ramachandran M; Essand M; Dimberg A
Front Immunol; 2023; 14():1275378. PubMed ID: 37954592
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Induction of Tertiary Lymphoid Structures in Cancer Through Stromal Remodeling.
Johansson-Percival A; Ganss R
Front Immunol; 2021; 12():674375. PubMed ID: 34122434
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of tertiary lymphoid structure formation: cooperation between inflammation and antigenicity.
Khanal S; Wieland A; Gunderson AJ
Front Immunol; 2023; 14():1267654. PubMed ID: 37809103
[TBL] [Abstract][Full Text] [Related]
13. Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response.
Zhang Q; Wu S
Front Immunol; 2022; 13():1063711. PubMed ID: 36713409
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic targets to enhance antitumor immune response through the induction of tertiary lymphoid structures.
Omotesho QA; Escamilla A; Pérez-Ruiz E; Frecha CA; Rueda-Domínguez A; Barragán I
Front Immunol; 2024; 15():1348156. PubMed ID: 38333212
[TBL] [Abstract][Full Text] [Related]
15. Targeting Tertiary Lymphoid Structures for Tumor Immunotherapy.
Tang H; Qiu X; Timmerman C; Fu YX
Methods Mol Biol; 2018; 1845():275-286. PubMed ID: 30141019
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer.
Sofopoulos M; Fortis SP; Vaxevanis CK; Sotiriadou NN; Arnogiannaki N; Ardavanis A; Vlachodimitropoulos D; Perez SA; Baxevanis CN
Cancer Immunol Immunother; 2019 Nov; 68(11):1733-1745. PubMed ID: 31598757
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation.
Salem D; Chelvanambi M; Storkus WJ; Fecek RJ
Front Immunol; 2021; 12():629519. PubMed ID: 33746966
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma.
Liu Z; Meng X; Tang X; Zou W; He Y
Cancer Immunol Immunother; 2023 Jun; 72(6):1505-1521. PubMed ID: 36481914
[TBL] [Abstract][Full Text] [Related]
19. Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy.
Rodriguez AB; Engelhard VH
Cancer Immunol Res; 2020 Nov; 8(11):1338-1345. PubMed ID: 33139300
[TBL] [Abstract][Full Text] [Related]
20. Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies.
Trüb M; Zippelius A
Front Immunol; 2021; 12():674565. PubMed ID: 34054861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
